ACADIA Pharmaceuticals Inc. (ACAD) Ownership
ACAD ownership summary
as of October 18, 2026- Institutions
- 100.0% of shares outstanding
- Insiders
- 0.33% of shares outstanding
- Shares outstanding
- 172.3M
- Float
- 128.4M shares available to trade
- Short interest
- 7.59% 8.3M shares short
- Days to cover
- 3.94 short interest down 14.4% vs prior month
- Institutions 100.05%
- Insiders 0.33%
ACAD top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Baker Bros Advisors LP | 24.91% | 42.9M | $820.5M | +16,214 (+0.0%) | June 30, 2026 |
| 2 | BlackRock Inc | 13.07% | 22.5M | $430.5M | +964,252 (+4.5%) | June 30, 2026 |
| 3 | State Street Corp | 5.27% | 9.1M | $173.5M | +743,441 (+8.9%) | June 30, 2026 |
| 4 | Vanguard Portfolio Management, LLC | 5.13% | 8.8M | $169.0M | +166,805 (+1.9%) | June 30, 2026 |
| 5 | RTW INVESTMENTS, LLC | 4.15% | 7.1M | $136.6M | — | June 30, 2026 |
| 6 | Vanguard Capital Management, LLC | 3.35% | 5.8M | $110.2M | +102,350 (+1.8%) | June 30, 2026 |
| 7 | Dimensional Fund Advisors, Inc. | 2.14% | 3.7M | $70.6M | +539,828 (+17.1%) | June 30, 2026 |
| 8 | Geode Capital Management, LLC | 1.95% | 3.4M | $64.2M | −106,560 (−3.1%) | June 30, 2026 |
| 9 | Palo Alto Investors, LLC | 1.66% | 2.9M | $54.8M | −8,599 (−0.3%) | June 30, 2026 |
| 10 | The Goldman Sachs Group Inc | 1.50% | 2.6M | $49.3M | +1.0M (+65.6%) | June 30, 2026 |
| 11 | Qube Research & Technologies | 1.42% | 2.4M | $46.8M | +1.5M (+157.5%) | June 30, 2026 |
| 12 | Point72 Asset Management, L.P. | 1.41% | 2.4M | $46.5M | −144,748 (−5.6%) | June 30, 2026 |
| 13 | Citadel Advisors Llc | 1.27% | 2.2M | $41.7M | +1.6M (+250.4%) | June 30, 2026 |
| 14 | Pictet Asset Manangement SA | 1.15% | 2.0M | $37.9M | −42,846 (−2.1%) | June 30, 2026 |
| 15 | Arrowstreet Capital Limited Partnership | 1.14% | 2.0M | $37.7M | +399,954 (+25.5%) | June 30, 2026 |
| 16 | Marshall Wace Asset Management Ltd | 1.02% | 1.8M | $33.7M | +1.7M (+2,216.5%) | June 30, 2026 |
| 17 | D. E. Shaw & Co LP | 0.99% | 1.7M | $32.5M | +968,101 (+132.6%) | June 30, 2026 |
| 18 | BRAIDWELL LP | 0.96% | 1.6M | $31.5M | −824,800 (−33.4%) | June 30, 2026 |
| 19 | NORGES BANK | 0.94% | 1.6M | $31.0M | +115,781 (+7.7%) | June 30, 2026 |
| 20 | Frazier Life Sciences Management, L.P. | 0.83% | 1.4M | $27.5M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 9.8M shares and 5 cut 1.1M.
ACAD top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | iShares Core S&P Small-Cap ETF | 4.47% | 7.7M | $147.1M | +1,809 (+0.0%) | September 30, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 2.37% | 4.1M | $78.1M | −8,562 (−0.2%) | August 31, 2026 |
| 3 | iShares Russell 2000 ETF | 1.93% | 3.3M | $63.7M | −38,400 (−1.1%) | September 30, 2026 |
| 4 | Vanguard Small Cap Index | 1.72% | 3.0M | $56.6M | +6,822 (+0.2%) | August 31, 2026 |
| 5 | State Street® SPDR® S&P® Biotech ETF | 1.44% | 2.5M | $47.6M | −47,550 (−1.9%) | September 30, 2026 |
| 6 | Vanguard MStar Small Cap Growth Indx Inv | 0.99% | 1.7M | $32.5M | −13,551 (−0.8%) | August 31, 2026 |
| 7 | Fidelity Small Cap Index | 0.82% | 1.4M | $26.9M | +11,682 (+0.8%) | July 31, 2026 |
| 8 | iShares Biotechnology ETF | 0.77% | 1.3M | $25.4M | −10,048 (−0.8%) | September 30, 2026 |
| 9 | iShares Russell 2000 Growth ETF | 0.70% | 1.2M | $23.1M | −1,531 (−0.1%) | September 30, 2026 |
| 10 | iShares S&P Small-Cap 600 Growth ETF | 0.69% | 1.2M | $22.9M | — | September 30, 2026 |
| 11 | State Street SPDR Port S&P 600 Sm CpETF | 0.68% | 1.2M | $22.5M | — | September 30, 2026 |
| 12 | Pictet-Biotech P USD | 0.65% | 1.1M | $21.3M | −4,509 (−0.4%) | June 30, 2026 |
| 13 | Artisan International Small-Mid Investor | 0.48% | 823K | $15.7M | +8,573 (+1.1%) | June 30, 2026 |
| 14 | Vanguard Tax-Managed Small Cap Adm | 0.47% | 812K | $15.5M | — | August 31, 2026 |
| 15 | State Street® SPDR® S&P 600™ Sm Cp GrETF | 0.43% | 744K | $14.2M | — | September 30, 2026 |
| 16 | Vanguard Russell 2000 ETF | 0.43% | 741K | $14.2M | +17,812 (+2.5%) | August 31, 2026 |
| 17 | Vanguard Strategic Equity Inv | 0.41% | 700K | $13.4M | — | June 30, 2026 |
| 18 | Schwab US Small-Cap ETF™ | 0.39% | 680K | $13.0M | +459 (+0.1%) | September 30, 2026 |
| 19 | Xtrackers MSCI World Swap ETF 1C | 0.37% | 646K | $12.3M | −4,066 (−0.6%) | December 31, 2025 |
| 20 | DFA US Small Cap I | 0.37% | 638K | $12.2M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ACAD insider transactions
latest 14| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | James Kihara | Sell | $22.20 | 1,030 | $22,866 |
| 2026-04-07 | Mark C Schneyer | Sell | $22.20 | 2,709 | $60,140 |
| 2026-02-09 | Jennifer J Rhodes | Sell | $23.38 | 6,950 | $162,491 |
| 2025-11-18 | James Kihara | Sell | $23.69 | 4,084 | $96,750 |
| 2025-11-18 | Mark C Schneyer | Sell | $23.69 | 10,262 | $243,107 |
| 2025-11-10 | James M Daly | Sell | $22.37 | 30,000 | $671,100 |
| 2025-09-15 | Mark C Schneyer | Sell | $23.65 | 3,498 | $82,728 |
| 2025-09-02 | Elizabeth A Garofalo | Sell | $25.98 | 1,600 | $41,568 |
| 2025-08-18 | Mark C Schneyer | Sell | $25.18 | 22,000 | $553,960 |
| 2025-06-04 | Laura Brege | Sell | $21.78 | 14,446 | $314,634 |
| 2025-05-16 | James Kihara | Sell | $22.50 | 4,000 | $90,000 |
| 2025-05-16 | Mark C Schneyer | Sell | $25.00 | 2,000 | $50,000 |
| 2025-05-02 | James Kihara | Sell | $14.60 | 1,327 | $19,374 |
| 2025-05-02 | Mark C Schneyer | Sell | $14.60 | 3,498 | $51,071 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ACAD shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ACAD
Institutional investors own 100.0% of ACADIA Pharmaceuticals's shares and insiders 0.33%. The largest holder is Baker Bros Advisors LP with 24.91% of the shares (42.9M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 5 reduced their stake in the latest filings. Short interest is 7.59% of the float, or 3.94 days of average trading volume. The share count rose 71.6% since 2014.
Related: ACAD analyst forecast, ACAD key metrics. See the ACAD stock overview for the latest quote and news.
ACAD ownership FAQ
Who owns the most ACADIA Pharmaceuticals stock?
The largest shareholders of ACADIA Pharmaceuticals are Baker Bros Advisors LP (24.91%), BlackRock Inc (13.07%), State Street Corp (5.27%), Vanguard Portfolio Management, LLC (5.13%), RTW INVESTMENTS, LLC (4.15%).
What percentage of ACADIA Pharmaceuticals is owned by institutions?
Institutions hold 100.0% of ACADIA Pharmaceuticals's shares outstanding; insiders hold 0.33%.
Which funds own ACADIA Pharmaceuticals?
The largest fund holders of ACADIA Pharmaceuticals are iShares Core S&P Small-Cap ETF (4.47%), Vanguard MStar Total Stk Mkt Idx Invest (2.37%), iShares Russell 2000 ETF (1.93%), Vanguard Small Cap Index (1.72%), State Street® SPDR® S&P® Biotech ETF (1.44%).
What is ACADIA Pharmaceuticals's short interest?
8.3M shares of ACADIA Pharmaceuticals were sold short, 7.59% of the float; at the average daily volume it would take 3.94 days to cover.
Are insiders buying or selling ACADIA Pharmaceuticals?
Of the latest 14 reported insider transactions in ACADIA Pharmaceuticals (since May 2, 2025), 0 were purchases and 14 were sales.
How many shares of ACADIA Pharmaceuticals are outstanding?
ACADIA Pharmaceuticals has 172.3M shares outstanding, of which 128.4M are in the public float.